Vasopressin V2 receptor antagonists

Journal of Molecular Endocrinology

Volumn 29, Issue 1, 2002, Pages 1-9

  Verbalis, J G ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ADENYLATE CYCLASE; ALDOSTERONE ANTAGONIST; AQUAPORIN 2; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CONIVAPTAN; DEMECLOCYCLINE; DESMOPRESSIN; DIURETIC AGENT; FUROSEMIDE; G PROTEIN COUPLED RECEPTOR; LITHIUM CARBONATE; LIXIVAPTAN; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; PHENOTHIAZINE DERIVATIVE; POTASSIUM ION; SEROTONIN UPTAKE INHIBITOR; SODIUM ION; TETRACYCLINE DERIVATIVE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V2 RECEPTOR ANTAGONIST; WATER; VASOPRESSIN RECEPTOR;

ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMYELINATING DISEASE; DIURESIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG INDUCED DISEASE; DRUG MECHANISM; HORMONE BLOOD LEVEL; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY COLLECTING TUBULE; NEPHROTOXICITY; NONHUMAN; PLASMA OSMOLARITY; PRIORITY JOURNAL; RAT; TREATMENT INDICATION; WATER PERMEABILITY; WATER RETENTION; ANIMAL; BLOOD; CLASSIFICATION; DRUG ANTAGONISM; REVIEW; SCHWARTZ BARTTER SYNDROME; SECRETION;

ANIMALS; ARGININE VASOPRESSIN; HUMANS; INAPPROPRIATE ADH SYNDROME; RECEPTORS, VASOPRESSIN;

EID: 0036668564     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.0.0290001     Document Type: Article

References (38)

1. Chronic hyponatremic encephalopathy in postmenopausal women: Association of therapies with morbidity and mortality
2. The syndrome of inappropriate secretion of antidiuretic hormone
3. 2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs
4. Role of vasopressin in abnormal water excretion in cirrhotic patients
5. 2 vasopressin receptor antagonist in normal subjects
6. 2 antagonist OPC-31260 in heart failure in the rat
7. 2 receptor antagonist
8. 2-receptor antagonist on kidney AQP2 expression and subcellular distribution
9. Effect of demethylchlorotetracycline on cellular action of antidiuretic hormone in vitro
10. Epidemiology, pathophysiology, and management of hyponatremic encephalopathy
11. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats
12. Arginine vasopressin and the renal response to water loading in congestive heart failure
13. The treatment of hyponatraemia using vasopressin antagonists
14. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats
15. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis
16. 2 receptor antagonist OPC-31260
17. Antidiuretic hormone antagonism in humans: Are there predictors?
18. Role of aquaporins in water balance disorders
19. Antagonists of vasopressin and oxytocin: Current status and future perspectives
20. 2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure
21. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs
22. Physiology and pathophysiology of renal aquaporins
23. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men
24. 2 antagonist in men
25. In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat
26. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
27. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1)
28. 2 receptor antagonist
29. 2 antagonist OPC-31260 in hydropenic humans
30. Neurologic sequelae after treatment of severe hyponatremia: A multicenter perspective
31. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo
32. Molecular pharmacology of human vasopressin receptors
33. Adaptation to acute and chronic hyponatremia: Implications for symptomatology, diagnosis, and therapy
34. SIADH and other hypo-osmolar disorders
35. 2 receptor antagonist
36. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1a and V2 receptor antagonist, in dogs
37. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure
38. Vasopressin function in the syndrome of inappropriate antidiuresis